Choice of upfront treatment in the management of diffuse large B-cell lymphoma and follicular lymphoma
|
|
- Fay Harvey
- 5 years ago
- Views:
Transcription
1 Choice of upfront treatment in the management of diffuse large B-cell lymphoma and follicular lymphoma Ryan Lynch MD Assistant Professor, University of Washington Assistant Member, Fred Hutchinson Cancer Research Center Seattle, Washington
2 Goals/outline Diffuse large B-cell lymphoma (DLBCL) Integrating components of IPI score with pathology information to create evidence-based treatment approach Hint: It isn t always R-CHOP x 6 Follicular lymphoma Approach to deciding which patients require systemic and/or local therapy If so, what should be used?
3 DLBCL background Most common lymphoma subtype 25% of non Hodgkin lymphomas (NHL) in developed world Possibly more frequent in Central and South America (up to 40%) Chemo-immunotherapy is curative in about 60% of patients R-CHOP x 6 every 21 days is standard
4 R-CHOP x 6 is superior to CHOP x 6 GELA, RICOVER-60, and MINT studies all demonstrated superiority of R-CHOP to CHOP GELA Subsequent studies over the past 10+ years have failed to find a standard that is superior in an unselected DLBCL population Feugier et al. JCO 2005
5 Alive (%) Dose dense therapy superior in older patients in pre-rituximab era CHOP-21 (n = 178) 40.6 CHOP-14 (n = 172) Yr OS, % CHOP-14 CHOP Pfreundschuh M, et al. Blood. 2004;104:
6 but no difference in the rituximab era Progression-free survival Cunningham et al Lancet 2013
7 What about a next generation anti-cd20 antibody? Obinutuzumab (Gazyva) Mossner et al Blood 2010
8 No difference between G-CHOP and R-CHOP Progression-free survival Vitolo et al. JCO 2017
9 Dose adjusted EPOCH-R Drug Route DL-2 DL-1 DL1 DL2 DL3 DL4 DL5 DL6 Prednisone PO 60 (mg/m 2 BID) Day 1-5 Rituximab IV 375 (mg/m 2 ) Day 1 Vincristine CIV 0.4 (mg/m 2 /day) Day 1-4 Etoposide CIV (mg/m 2 /day) Day 1-4 Doxorubicin CIV (mg/m 2 /day) Day 1-4 Cyclophosphamide (mg/m 2 ) Day 5 IV GCSF Day 7 onward until ANC > 1000/μL SC 300 μg/day (if <75 kg) or 480 μg/day (if 75 kg) Dose escalated for next cycle if ANC > 500/uL De-escalate if ANC < 500/uL for 3 days or platelets < 25K/uL at any time Goal to maximize chemotherapy intensity in patients who can tolerate it DL -1-2: Original protocol did not reduce etoposide and doxorubicin, but reasonable to do so
10 CALGB R-CHOP x 6 vs. DA-EPOCH-R x 6 Randomized phase III study Untreated, newly diagnosed stage II-IV DLBCL (stage I PMBCL), ECOG PS 0-2, LVEF > 45%, tumor biopsies available, no CNS disease (N = 465) DA-EPOCH-R R-CHOP 6 cycles Primary endpoint: EFS Secondary endpoints: RR OS Safety *Included CNS prophylaxis if BM/testicular involvement or elevated LDH plus 2 extranodal sites. Prophylaxis: MTX IT x 4 doses on Day 1 of Cycles 3-6. Wilson WH, et al. ASH Abstract 469. Wilson WH, et al. Blood. 2002;99:
11 CALGB Results No significant difference in response rates between treatment arms Subset analysis pending Wilson WH, et al. ASH Abstract 469.
12 EFS (%) OS (%) CALGB 50303: No difference in EFS and OS EFS OS HR: 1.14 (95% CI: ; P =.4386) HR: 1.18 (95% CI: ; P =.42) 20 0 R-CHOP DA-EPOCH-R Yrs 20 0 R-CHOP DA-EPOCH-R Yrs *Median follow-up 5 yrs Wilson WH, et al. ASH Abstract 469.
13 CALGB/Alliance 50303: Increased toxicity with EPOCH-R Wilson WH, et al. ASH Abstract 469.
14 SWOG 9704: ASCT in CR/PR1 (IPI 3-5) Improved PFS, but no OS benefit Stiff et al. N Engl J Med 2013
15 I didn t come here to tell you to give R-CHOP x 6 to every patient with aggressive B-cell NHL
16 R-CHOP x 6 remains standard for untreated in unselected patients DLBCL However, DLBCL is a heterogeneous disease, and much has been learned since CALGB was designed in 2005 Subsets of patients may benefit from altered approach
17 International Prognostic Index (IPI) Age > 60 Performance status > 1 LDH elevated Extranodal sites > 1 Stage III/IV Validated in rituximab era as predictor of outcome Ziepert et al JCO 2010
18 Age > 60 Performance status > 1 LDH elevated Extranodal sites > 1 Stage III/IV
19 How to approach a new diagnosis of DLBCL Age > 60 Performance status > 1 Pathology/FISH LDH elevated Extranodal sites > 1 Stage III/IV
20 How to approach a new diagnosis of DLBCL Age > 60 Performance status > 1 Pathology/FISH LDH elevated Extranodal sites > 1 Stage III/IV
21 Can early stage DLBCL patients receive abbreviated therapy?
22 In pre-rituximab era, abbreviated chemo-rt superior to chemo alone CHOP x 3 + RT N= 401 CHOP x 8 Miller NEJM 339:21, 1998
23 Abbreviated chemo/rt for early stage DLBCL in rituximab era Retrospective data (Odejide et al 2015) and phase II data (Persky et al 2008) show excellent outcomes with R-CHOP x RT UNFOLDER EFS benefit to 6 R-CHOP + RT in >7.5 cm lesions Lysa no benefit to RT in non-bulky disease with R-CHOP 4-6 Adapted from Ng et al JCO 2016
24 How to approach a new diagnosis of DLBCL Age > 60 Performance status > 1 Pathology/FISH LDH elevated Extranodal sites > 1 Stage III/IV
25 Limited data in elderly (age > 80) SEER data R-CHOP associated with improved survival on multivariate analysis R-mini-CHOP ~50% dosing, including doxorubicin 2 year OS 59% TRM 8.1% Williams et al. Cancer 2015 Peyrade et al Lancet Oncol 2011
26 Poor performance status or heart failure R-CEOP a reasonable option for a patient with decreased ejection fraction or co-morbidities Adjust dose to ensure patient tolerance R-CVP palliative in most patients
27 How to approach a new diagnosis of DLBCL Age > 60 Performance status > 1 Pathology/FISH LDH elevated Extranodal sites > 1 Stage III/IV
28 WHO 2016 Update High grade B-cell lymphoma (HGBL), with MYC and BCL2 and/or BCL6 rearrangements Double (DHL) or triple-hit lymphomas (THL) Gene rearrangements by FISH/cytogenetics (not protein expression) HGBL, not otherwise specified Similar to entity previously called BCLU or Burkitt-like Blastoid appearance but lack specific features of BL, MCL, or B- LBL Swerdlow et al Blood 2016
29 High grade B-cell lymphoma with rearrangements of MYC and BCL2 and/or BCL6 Also known as double hit lymphoma (DHL) DHL associated with inferior outcomes with R- CHOP Double protein/expressor lymphoma (DEL) Increased IHC staining for MYC (>40%) and BCL2 (>50%) Outcomes with R-CHOP Johnson NA, et al: J Clin Oncol 30:3452-9, 2012
30 Should we use intensified regimens in DHL and DEL?
31 R-CHOP vs Intensified Regimens in DHL Petrich et al. Blood 2014;124:
32 Petrich et al. Blood 2014;124: DHL: PFS by Induction Regimen
33 Prospective study DA-EPOCH-R x 6 in MYC rearranged DLBCL No prospective or randomized evidence to support the use of DA- EPOCH-R in DEL Prospective phase II DA-EPOCH-R x 6 cycles Dunleavy K, et al: ASH 2014 Median follow up 14 months 52 patients All patients with MYC rearrangement, 45% with concurrent BCL2 rearrangement
34 Primary mediastinal (thymic) B-cell lymphoma is a Median age 35 Females > males (2:1) distinct subtype Dominant mediastinal mass with direct extranodal extension or involvement of neighboring lymph node chains Less common advanced stage or BM involvement Path: bands of sclerosis, often with CD30+, can resemble Hodgkin lymphoma Surface immunoglobulin neg, but CD19+, CD20+, CD79a+
35 DA-EPOCH-R upfront in PMBCL NCI 51 patients (prospective) Median follow up 5 years Stanford 17 patients (retrospective) Median follow up 3 years Dunleavy K, et al: N Engl J Med 368: , 2013
36 Primary mediastinal large B-cell lymphoma Limited stage R-CHOP x 6 + IFRT DA-EPOCH-R x 6 without RT Advanced stage DA-EPOCH-R x 6 Refractory or relapsed disease very challenging to treat
37 ABC vs. GCB Cell of origin is important in DLBCL Activated B-cell type (ABC) vs. germinal center B-cell type (GCB) However, no randomized data to support escalated regimens beyond R- CHOP, though studies are ongoing Gutierrez-Garcia G, et al. Blood 2011; 117:4836
38 DLBCL: Other induction regimens under study Ibrutinib + R-CHOP: (phase III)- ABC subtype only Lenalidomide + R-CHOP: (phase III)-ABC subtype only Brentuximab-vedotin + R-CHP CD30+ (at least 1%) phase III closed due to poor accrual
39 Summary MYC rearranged/dhl/thl: DA-EPOCH-R or Burkitt-like regimen (R- CODOX-M/R-IVAC) DEL: controversial. R-CHOP vs. DA-EPOCH-R (I like clinical trials) High grade B-cell lymphoma NOS: DA-EPOCH-R vs. Burkitt-like regimen ABC DLBCL: R-CHOP x 6 (for now) Challenges in translating promising phase II data into successful phase III randomized clinical trials!
40 How to approach a new diagnosis of DLBCL Age > 60 Performance status > 1 Pathology/FISH LDH elevated Extranodal sites > 1 Stage III/IV
41 Who needs CNS prophylaxis Highly aggressive B-cell NHL Lymphoblastic lymphoma Burkitt lymphoma Intravascular DLBCL CD5+ DLBCL MYC rearranged DLBCL (including DHL and THL) Double expressor DLBCL (IHC, BCL2 > 50%, MYC > 40%)
42 Who needs CNS prophylaxis DLBCL Elevated LDH and > 1 extranodal site Involvement of the testes, orbit, breast or epidural space Bone marrow involvement CNS IPI score
43 CNS IPI Patients with score of 4-6 (CNS relapse risk >5%) should receive CNS prophylaxis Number of Factors 0-1 < CNS Relapse Risk (%) Schmitz et al. JCO 2016
44 What to use for CNS prophylaxis? Should be incorporated into regimen for high risk histologies (R- CODOX-M/R-IVAC, R-hyper-CVAD) Burkitt, lymphoblastic, select cases of high grade B-cell lymphoma NOS (younger patients) Mid-cycle IV methotrexate (3.5 g/m2) x 3 vs. intrathecal Consider IV for high risk DLBCL patients (Abutting CNS, sinus involvement, many risk factors) Intrathecal methotrexate 12 mg x 4 cycles likely sufficient for most cases No prospective data
45 Other considerations Bulky disease Allopurinol 300 mg once or twice per day started at least 1-2 days prior to treatment and continuing for at least 1 week Oral hydration High risk patients should be admitted and monitored with serial labs and rasburicase PRN Baseline Hepatitis B, C, and HIV testing HIV entire lectures can be dedicated to this topic alone and choice of therapy can be different Hepatitis B risk of reactivation prophylaxis needed! Baseline Echo EF of at least 50% for doxorubicin Can substitute etoposide for depressed EF
46 Summary Stage I/II: R-CHOP x 3 + RT or R-CHOP x 6 reasonable Site > 7.5 cm R-CHOP x 6 and consider RT Age > 80 or poor performance status Consider R-mini-CHOP or R-CEOP (if depressed EF) Aggressive histologies PMBCL, DHL/THL, MYC rearranged, HGBCL: Intensified regimen CNS prophylaxis Don t forget to use on patients with risk factors!
47 Follicular lymphoma Most common subtype of indolent B-cell NHL Nodular growth pattern effaces normal lymphoid architecture 85% of patients have t(14;18) translocation Most common immunophenotype CD10+, CD19+, CD20+, BCL6+, BCL2+, CD5-, CD23- FL treatment is rarely curative Patients living longer (manage like a chronic disease) Median OS in rituximab era has not been reached (Tan et al JCO 2013)
48 Follicular Lymphoma - Grading Grade 1-2 Grade 1 (follicular small cleaved cell) ~45% < 15% centroblasts Grade 2 (follicular mixed small & large cell) ~27% Grade 3 (follicular large cell) ~27% Images courtesy of J. Connors, MD from slide adapted from Ajay Gopal MD
49 Grade 3 Follicular Lymphoma Feature Grade 3A Grade 3B Centrocytes Present Absent Diffuse areas Absent Present BM involvement Frequent Uncommon CD10 100% 50% BCL2 ~75% ~75% t(14;18) 73% 13% BCL6 rearrangements 18% 44% Controversial area, Grade 3A generally treated like FL Less controversial: Grade 3B treated like DLBCL Ott et al, Blood 2002 May 15;99(10): (Horn et al. Haematologica Sep;96(9): doi:
50 Indications for treatment: GELF criteria Tumor bulk One site > 7 cm, or 3 sites > 3 cm Systemic symptoms Splenomegaly Vital organ compromise Effusions Circulating lymphoma cells > 5000/uL Cytopenias (Neutrophils < 1000/uL, Platelets < 100K / ul Histologic Transformation treat like DLBCL
51 Stage I/II follicular lymphoma No randomized trials RT alone may be curative Stanford experience: 40% 10 year relapse free survival Most retrospective analyses used higher doses, but Gy likely sufficient Concurrent RT with rituximab +/- chemo unlikely to provide added benefit (mixed retrospective data) Systemic therapy alone (rituximab +/- chemo reserved for symptomatic patients with a contraindication to definitive RT Site of disease Age of patient/risk of secondary malignancy Mac Manus MP,. J Clin Oncol 14: , 1996
52 Early stage FL: observation No initial therapy 43 evaluable patients Median age= 58 yrs Median OS= 19 yrs 10yr OS = 86% 10yr treatment-free survival=56% Advani et al JCO 2004
53 Should I treat asymptomatic advanced FL?
54 Advanced stage asymptomatic FL: Chlorambucil vs Observation Median Survival p=0.84 Observation 6.7 yr Asymptomatic Stage III/IV FL n=309 Chl 10mg/day 5.9 yrs 19% did not require treatment at 10 years! Ardeshna et al, Lancet. 2003
55 Asymptomatic advanced stage FL: Rituximab vs Observation Time to next therapy Overall Survival 46% did not need treatment at 3 yrs! No improvement in QOL 1:1:1 randomization, with induction only arm eventually closed Rituximab induction 375 mg/m2 weekly x 4 Maintenance every 2 months x 2 years Ardeshna et al Lancet Oncol Apr;15(4):
56 Evolution of the management of symptomatic advanced stage FL in the rituximab era TTF PFS R-FM R-CHOP R-CVP Least toxic: R-CVP->R-CHOP->R-FM: Most Toxic Federico et al. JCO 2013
57 Is there benefit to maintenance rituximab? Untreated advanced stage FL 6 cycles R-CHOP, then randomized to maintenance vs. observation Median f/u 72 months PFS benefit, but no OS benefit Salles G et al, Lancet 2013
58 PFS STIL and BRIGHT trials R-bendamustine vs. R-CHOP in follicular lymphoma without transformation PFS benefit STIL Time (Months) BRIGHT trial R-B noninferior to R-CHOP/R-CVP by primary endpoint of CR rate Less toxicity with R-B vs. R-CHOP Flinn IW, et al: Blood 123: , 2014 Rummel MJ, et al: Lancet 381: , 2013
59 OS PFS End of Induction FDG-PET is associated with improved outcome PET - PET + p<.001 PET - PET + p=.001 Trotman et al. J Clin Oncol Aug 10;29(23):
60 Impact of 2 year initial TTP on OS after R-CHOP Risk of progression over time Survival by early (< 2 year) vs late progression High-early relapse risk POD: progression of disease Casulo et al. J Clin Oncol Aug 10;33(23):
61 Histologic transformation of follicular lymphoma Occurs at rate of 2-3%/year Transformation after previous anthracycline-based chemotherapy is associated with poor outcomes Single-agent rituximab or R-bendamustine considered inadequate R-CHOP is considered standard in naïve patients Consider platinum-containing regimens in those who previous received CHOP-like regimen (R-ICE, R-DHAP) Role of auto-hsct is controversial (no randomized evidence in rituximab era)
62 Histologic transformation of follicular lymphoma Outcomes similar between HT and de novo DLBCL with R-CHOP Anthracycline use prior to transformation associated with worse outcomes Link BK, et al: J Clin Oncol 31:3272-8, 2013
63 Role of auto HSCT after HT of follicular lymphoma Retrospective review of PRIMA trial suggests that patients who have HT after previous immunochemotherapy may benefit from auto HSCT as part of salvage No clear benefit for those who relapse with persistent FL histology
64 Other notes FL is rarely cured goal of treatment is to relieve symptoms and maximize reimssion duration/treatment-free interval Minimize toxicity High index of suspicion for transformation Bulk, rapid growth of single site, site more FDG avid than others Adjust therapy based on prognosis Age Comorbidities Early treatment does not prolong survival or prevent histologic transformation
65 Early stage: RT potentially curative Summary Advanced Stage Observe if no indication for treatment Grade 1-2: Low Tumor Burden- Rituximab alone or R-Bendamustine High-tumor Burden- R-Bendamustine Grade 3 Grade 3A: R-bendamustine (low threshold to escalate) Grade 3B: R-CHOP Histologic transformation R-CHOP or anthracycline based therapy (if not already received) I do not prefer R-maintenance due to lack of OS benefit (but still controversial)? Increased risk of death/infection, GALLIUM study
66 Questions? Thank you!
The treatment of DLBCL. Michele Ghielmini Medical Oncology Dept Oncology Institute of Southern Switzerland Bellinzona
The treatment of DLBCL Michele Ghielmini Medical Oncology Dept Oncology Institute of Southern Switzerland Bellinzona NHL frequency at the IOSI Mantle Cell Lymphoma 6.5 % Diffuse Large B-cell Lymphoma 37%
More informationNON HODGKINS LYMPHOMA: INDOLENT Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary)
NON HODGKINS LYMPHOMA: INDOLENT Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary) Reviewed by Dr. Michelle Geddes (Staff Hematologist, University of Calgary) and Dr.
More informationDiffuse Large B-Cell Lymphoma (DLBCL)
Diffuse Large B-Cell Lymphoma (DLBCL) DLBCL/MCL Dr. Anthea Peters, MD, FRCPC University of Alberta/Cross Cancer Institute Disclosures Honoraria from Janssen, Abbvie, Roche, Lundbeck, Seattle Genetics Objectives
More informationHave we moved beyond EPOCH for B-cell non-hodgkin lymphoma? YES!
Have we moved beyond EPOCH for B-cell non-hodgkin lymphoma? YES! Christopher Flowers, MD, MSc Associate Professor Director, Lymphoma Program Department of Hematology and Oncology Emory School of Medicine
More informationPET-adapted therapies in the management of younger patients (age 60) with classical Hodgkin lymphoma
PET-adapted therapies in the management of younger patients (age 60) with classical Hodgkin lymphoma Ryan Lynch MD Assistant Professor, University of Washington Assistant Member, Fred Hutchinson Cancer
More informationNew Targets and Treatments for Follicular Lymphoma
Winship Cancer Institute of Emory University New Targets and Treatments for Follicular Lymphoma Jonathon B. Cohen, MD, MS Assistant Professor Div of BMT, Emory University Intro/Outline Follicular lymphoma,
More informationAggressive B and T cell lymphomas: Treatment paradigms in 2018
Aggressive B and T cell lymphomas: Treatment paradigms in 2018 John P. Leonard M.D. Richard T. Silver Distinguished Professor of Hematology and Medical Oncology Associate Dean for Clinical Research Associate
More informationWhat are the hurdles to using cell of origin in classification to treat DLBCL?
What are the hurdles to using cell of origin in classification to treat DLBCL? John P. Leonard, M.D. Richard T. Silver Distinguished Professor of Hematology and Medical Oncology Associate Dean for Clinical
More informationUpdate: Non-Hodgkin s Lymphoma
2008 Update: Non-Hodgkin s Lymphoma ICML 2008: Update on non-hodgkin s lymphoma Diffuse Large B-cell Lymphoma Improved outcome of elderly patients with poor-prognosis diffuse large B-cell lymphoma (DLBCL)
More informationB Cell Lymphoma: Aggressive
B Cell Lymphoma: Aggressive UpToDate: Introduction: Risk Factors: Biology: Symptoms: Diagnosis: Ibrutinib approved for mantle cell lymphoma as 2nd line therapy. - Aggressive lymphomas are a group of malignant
More information12 th Annual Hematology & Breast Cancer Update Update in Lymphoma
12 th Annual Hematology & Breast Cancer Update Update in Lymphoma Craig Okada, MD, PhD Assistant Professor, Hematology January 14, 2010 Governors Hotel, Portland Oregon Initial Treatment of Indolent Lymphoma
More informationLancashire and South Cumbria Haematology NSSG Guidelines for Follicular Lymphoma:
1 Lancashire and South Cumbria Haematology NSSG Guidelines for Follicular Lymphoma: 2018-19 1.1 Pretreatment evaluation The following tests should be performed: FBC, U&Es, creat, LFTs, calcium, LDH, Igs/serum
More informationNON HODGKINS LYMPHOMA: AGGRESSIVE Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary)
NON HODGKINS LYMPHOMA: AGGRESSIVE Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary) Reviewed by Dr. Michelle Geddes (Staff Hematologist, University of Calgary) and
More informationSEQUENCING FOLLICULAR LYMPHOMA
SEQUENCING FOLLICULAR LYMPHOMA Thomas E. Witzig, MD October 24, 2015 Disclosures All presenters were independently selected by the organizing committee. Those presenters who disclosed affiliations or financial
More informationThe case against maintenance rituximab in Follicular lymphoma. Jonathan W. Friedberg M.D., M.M.Sc.
The case against maintenance rituximab in Follicular lymphoma Jonathan W. Friedberg M.D., M.M.Sc. Follicular lymphoma: What are goals of treatment? Change natural history of disease: Decrease transformation
More informationRadiotherapy in DLCL is often worthwhile. Dr. Joachim Yahalom Memorial Sloan-Kettering, New York
Radiotherapy in DLCL is often worthwhile Dr. Joachim Yahalom Memorial Sloan-Kettering, New York The case for radiotherapy Past: Pre-Rituximab randomized trials Present: R-CHOP as backbone, retrospective
More informationESMO DOUBLE-HIT LYMPHOMAS
ESMO DOUBLE-HIT LYMPHOMAS Professor Dr. med. Georg Lenz Director Department of Hematology and Oncology Universitätsklinikum Münster, Germany OVERVIEW Definition of double-hit lymphomas Introduction in
More informationRituximab in the Treatment of NHL:
New Evidence reports on presentations given at ASH 2010 Rituximab in the Treatment of NHL: Rituximab versus Watch and Wait in Asymptomatic FL, R-Maintenance Therapy in FL with Standard or Rapid Infusion,
More informationBrad S Kahl, MD. Tracks 1-21
I N T E R V I E W Brad S Kahl, MD Dr Kahl is Associate Professor and Director of the Lymphoma Service at the University of Wisconsin School of Medicine and Public Health and Associate Director for Clinical
More informationHead and Neck: DLBCL
Head and Neck: DLBCL Nikhil G. Thaker Chelsea C. Pinnix Valerie K. Reed Bouthaina S. Dabaja Department of Radiation Oncology MD Anderson Cancer Center Case 60 yo male Presented with right cervical LAD
More informationDiffuse Large B-Cell Lymphoma Front line Therapy John P. Leonard, MD Weill Cornell Medicine New York, New York USA
Diffuse Large B-Cell Lymphoma Front line Therapy John P. Leonard, MD Weill Cornell Medicine New York, New York USA Disclosures Consulting advice: Hospira, Bayer, Juno Therapeutics, Teva, Oncotracker, Gilead
More informationRadiotherapy in aggressive lymphomas. Umberto Ricardi
Radiotherapy in aggressive lymphomas Umberto Ricardi Is there (still) a role for Radiation Therapy in DLCL? NHL: A Heterogeneous Disease ALCL PMLBCL (2%) Burkitt s MCL (6%) Other DLBCL (31%) - 75% of aggressive
More informationDr. A. Van Hoof Hematology A.Z. St.Jan, Brugge. ASH 2012 Atlanta
Dr. A. Van Hoof Hematology A.Z. St.Jan, Brugge ASH 2012 Atlanta DLBCL How to improve on R-CHOP What at relapse Mantle cell lymphoma Do we cure patients Treatment at relapse Follicular lymphoma Watch and
More informationStrategies for the Treatment of Elderly DLBCL Patients, New Combination Therapy in NHL, and Maintenance Rituximab Therapy in FL
New Evidence reports on presentations given at ASH 2009 Strategies for the Treatment of Elderly DLBCL Patients, New Combination Therapy in NHL, and Maintenance Rituximab Therapy in FL From ASH 2009: Non-Hodgkin
More informationHow I approach newly diagnosed Follicular Lymphoma patients with advanced stage? Professeur Gilles SALLES
How I approach newly diagnosed Follicular Lymphoma patients with advanced stage? Professeur Gilles SALLES How I Choose First Line Treatment in Follicular Lymphoma in 2017? 1. How do I take into account
More informationCARE at ASH 2014 Lymphoma. Dr. Diego Villa Medical Oncologist British Columbia Cancer Agency Vancouver Cancer Centre
CARE at ASH 2014 Lymphoma Dr. Diego Villa Medical Oncologist British Columbia Cancer Agency Vancouver Cancer Centre High-yield lymphoma sessions Sat, Dec 6 th Sun, Dec 7 th Mon, Dec 8 th EDUCATIONAL SESSIONS
More informationPolicy for Central Nervous System [CNS] Prophylaxis in Lymphoid Malignancies
Policy for Central Nervous System [CNS] Prophylaxis in Lymphoid Malignancies UNCONTROLLED WHEN PRINTED Note: NOSCAN Haematology MCN has approved the information contained within this document to guide
More informationManagement of high-risk diffuse large B cell lymphoma: case presentation
Management of high-risk diffuse large B cell lymphoma: case presentation Daniel J. Landsburg, MD Assistant Professor of Clinical Medicine Perelman School of Medicine University of Pennsylvania January
More informationIl trattamento del Linfoma Follicolare in prima linea
Il trattamento del Linfoma Follicolare in prima linea Dr.ssa Carola Boccomini SC Ematologia Dr. U. Vitolo AO Città della Salute e della Scienza Torino, Italy Median follow-up 3 years Median follow-up 6
More informationCAR-T cell therapy pros and cons
CAR-T cell therapy pros and cons Stephen J. Schuster, MD Professor of Medicine Perelman School of Medicine of the University of Pennsylvania Director, Lymphoma Program & Lymphoma Translational Research
More informationOSCO/OU ASH-SABC Review. Lymphoma Update. Mohamad Cherry, MD
OSCO/OU ASH-SABC Review Lymphoma Update Mohamad Cherry, MD Outline Diffuse Large B Cell Lymphoma Double Hit Lymphoma Follicular and Indolent B Cell Lymphomas Mantle Cell Lymphoma T Cell Lymphoma Hodgkin
More informationDr. Nicolas Ketterer CHUV, Lausanne SAMO, May 2009
Treatment of DLBCL Dr. Nicolas Ketterer CHUV, Lausanne SAMO, May 2009 Non-hodgkin lymphomas DLBCL Most common NHL subtype throughout the world many other types of lymphoma with striking geographic variations
More informationLymphoma Christophe BONNET Centre Hospitalier Universitaire, Ulg, Liège. 14 th post-ash meeting, January 6 th 2011, Brussels
Lymphoma Christophe BONNET Centre Hospitalier Universitaire, Ulg, Liège 14 th post-ash meeting, January 6 th 2011, Brussels Hodgkin s lymphoma Follicular lymphoma Diffuse large B-cell lymphoma Mantle cell
More informationMantle Cell Lymphoma: Update in Diego Villa, MD MPH FRCPC Medical Oncologist BC Cancer Agency
Mantle Cell Lymphoma: Update in 2015 Diego Villa, MD MPH FRCPC Medical Oncologist BC Cancer Agency Disclosures Research funding: Roche provides research funding to support the Centre for Lymphoid Cancer
More informationOpen questions in the treatment of Follicular Lymphoma. Prof. Michele Ghielmini Head Medical Oncology Dept Oncology Institute of Southern Switzerland
Open questions in the treatment of Follicular Lymphoma Prof. Michele Ghielmini Head Medical Oncology Dept Oncology Institute of Southern Switzerland Survival of major lymphoma subtypes at IOSI 1.00 cause-specific
More informationDouble hit lymphoma Clinical perspectives
Double hit lymphoma Clinical perspectives Peter Johnson Some definitions, for clarity Double-hit lymphoma (5% of DLBL) Rearranged MYC (8q24) by FISH Plus either rearranged BCL2 (18q21) or BCL6 (3q27) Double-expression
More informationAggressive B-cell lymphomas and gene expression profiling towards individualized therapy?
Aggressive B-cell lymphomas and gene expression profiling towards individualized therapy? Andreas Rosenwald Institute of Pathology, University of Würzburg, Germany Barcelona, June 18, 2010 NEW WHO CLASSIFICATION
More informationFollicular Lymphoma 2016:
Follicular Lymphoma 2016: Evolving Management Strategies Randeep Sangha, MD Medical Oncology, Cross Cancer Institute Associate Professor, University of Alberta Edmonton, AB Disclosures I have no actual
More informationAggressive lymphomas ASH Dr. A. Van Hoof A.Z. St.Jan, Brugge-Oostende AV
Aggressive lymphomas ASH 2015 Dr. A. Van Hoof A.Z. St.Jan, Brugge-Oostende AV CHOP 1992 2002 R-CHOP For DLBCL High dose chemo With PBSCT Aggressive lymphomas 1.DLBCL 2.Primary Mediastinal Lymphoma 3.CNS
More informationNon-Hodgkin s and Hodgkin lymphoma: using disease characteristics as a guide to treatment selection. Arnold Freedman, M.D.
2017 Master Class for Oncologists Non-Hodgkin s and Hodgkin lymphoma: using disease characteristics as a guide to treatment selection Arnold Freedman, M.D. 2018 Master Class Course Disclosure Disclosure
More information2012 by American Society of Hematology
2012 by American Society of Hematology Common Types of HIV-Associated Lymphomas DLBCL includes primary CNS lymphoma (PCNSL) Burkitt Lymphoma HIV-positive patients have a 60-200 fold increased incidence
More informationFollicular Lymphoma. Michele Ghielmini. Oncology Institute of Southern Switzerland Bellinzona
Follicular Lymphoma Michele Ghielmini Oncology Institute of Southern Switzerland Bellinzona Conflicts of interest Astra Zeneca Roche Cellgene Mundipharma Janssen Gilead Bayer Abbvie FL remains an incurable
More informationNon-Hodgkin Lymphoma in Clinically Difficult Situations
Winship Cancer Institute of Emory University Non-Hodgkin Lymphoma in Clinically Difficult Situations James Armitage, MD Professor, Department of Internal Medicine Joe Shapiro Distinguished Chair of Oncology
More informationLymphoma Update 2018
Lymphoma Update 2018 Sonali M. Smith, MD Elwood V. Jensen Professor of Medicine Section of Hematology/Oncology Director, Lymphoma Program The University of Chicago April 18, 2018 Disclosure Information
More informationFOLLICULAR LYMPHOMA: US vs. Europe: different approach on first relapse setting?
Indolent Lymphoma Workshop Bologna, Royal Hotel Carlton May 2017 FOLLICULAR LYMPHOMA: US vs. Europe: different approach on first relapse setting? Armando López-Guillermo Department of Hematology, Hospital
More informationAggressive NHL and Hodgkin Lymphoma. Dr. Carolyn Faught November 10, 2017
Aggressive NHL and Hodgkin Lymphoma Dr. Carolyn Faught November 10, 2017 What does aggressive mean? Shorter duration of symptoms Generally need treatment at time of diagnosis Immediate, few days, few weeks
More informationMantle Cell Lymphoma
Mantle Cell Lymphoma Clinical Case A 56 year-old woman complains of pain and fullness in the left superior abdominal quadrant for the last 8 months. She has lost 25 kg, and lately has had night sweats.
More informationACCME/Disclosures. DLBCL, NOS from the clinician perspective. Diffuse large B cell lymphoma
, NOS from the clinician perspective John P. Leonard, M.D. Weill Cornell Medicine New York Presbyterian Hospital ACCME/Disclosures The USCAP requires that anyone in a position to influence or control the
More informationWho should get what for upfront therapy for MCL? Kami Maddocks, MD The James Cancer Hospital The Ohio State University
Who should get what for upfront therapy for MCL? Kami Maddocks, MD The James Cancer Hospital The Ohio State University Treatment Challenges Several effective options, improve response durations, none curable
More informationHighlights of ICML 2015
Highlights of ICML 2015 Jonathan W. Friedberg M.D. Director, James P. Wilmot Cancer Center Statistics, ICML 2015: a global meeting Almost 3700 participants. 90 countries represented. Attendees: USA 465
More informationHigh grade B-cell lymphomas (HGBL): Altered terminology in the 2016 WHO Classification (Update of the 4 th Edition) and practical issues Xiao-Qiu Li,
High grade B-cell lymphomas (HGBL): Altered terminology in the 2016 WHO Classification (Update of the 4 th Edition) and practical issues Xiao-Qiu Li, M.D., Ph.D. Fudan University Shanghai Cancer Center
More informationSolomon Graf, MD February 22, 2013
Solomon Graf, MD February 22, 2013 Case Review of FL pathology, prognosis Grading of FL Grade 3 disease High proliferative index in grade 1/2 disease Pediatric FL Future of FL classification 57 yo man
More informationNew Evidence reports on presentations given at EHA/ICML Bendamustine in the Treatment of Lymphoproliferative Disorders
New Evidence reports on presentations given at EHA/ICML 2011 Bendamustine in the Treatment of Lymphoproliferative Disorders Report on EHA/ICML 2011 presentations Efficacy and safety of bendamustine plus
More informationHow to Refine Treatment Choice in Follicular Lymphoma: From Low-Tumor Burden to High-Risk Follicular Lymphoma
How to Refine Treatment Choice in Follicular Lymphoma: From Low-Tumor Burden to High-Risk Follicular Lymphoma Peter A. Riedell, MD and Brad S. Kahl, MD Abstract Follicular lymphoma (FL) is the most common
More informationConflict of Interest Disclosure Form NAME :James O. Armitage, M.D AFFILIATION: University of Nebraska Medical Center
What Is Personalized Medicine For Patients With Lymphoma? Conflict of Interest Disclosure Form NAME :James O. Armitage, M.D AFFILIATION: University of Nebraska Medical Center DISCLOSURE I have no potential
More informationTargeted Radioimmunotherapy for Lymphoma
Targeted Radioimmunotherapy for Lymphoma John Pagel, MD, PhD Fred Hutchinson Cancer Center Erik Mittra, MD, PhD Stanford Medical Center Brought to you by: Financial Disclosures Disclosures Erik Mittra,
More informationChallenges in the Treatment of Follicular Lymphoma
Challenges in the Treatment of Follicular Lymphoma Prof. Michele Ghielmini Clinical Director Oncology Institute of Southern Switzerland Bellinzona ESMO guidelines 2014 (simplified) Low tumor burden High
More informationGLSG/OSHO Study Group. Supported by Deutsche Krebshilfe
GLSG/OSHO Study Group Supported by Deutsche Krebshilfe founded in 1985 Comparison of Two Consecutive Study Generations of the GLSG Overall Survival Follicular Lymphomas Questions for the Next Steps of
More informationPatient Case Studies & Panel Discussion
Patient Case Studies & Panel Discussion Panelists: Jeremy S. Abramson, MD, Massachusetts General Hospital Cancer Center; Ranjana H. Advani, MD, Stanford Cancer Institute; Andrew D. Zelenetz, MD, PhD, Memorial
More informationThe case for maintenance rituximab in FL
New-York, October 23 rd 2015 The case for maintenance rituximab in FL Pr. Gilles SALLES For FL patients, progression-free survival still needs to be improved Median R-CHVP-I 66 months P
More informationPost-ESMO Berne
Post-ESMO Berne 23.10.2015 Lymphoma Update Panagiotis Samaras Department of Oncology Hemato-Oncology Center University Hospital Zurich Diffuse Large B-Cell Lymphoma (DLBCL) PCNSL Hodgkin s Lymphoma Mantle
More informationTreating for Cure or Palliation: Difficult Decisions for Older Adults with Lymphoma
Treating Frail Adults With Common Malignancies: Best Evidence to Personalize Therapy Treating for Cure or Palliation: Difficult Decisions for Older Adults with Lymphoma Raul Cordoba, MD, PhD Lymphoma Unit
More informationBendamustine, Bortezomib and Rituximab in Patients with Relapsed/Refractory Indolent and Mantle-Cell Non-Hodgkin Lymphoma
Bendamustine, Bortezomib and Rituximab in Patients with Relapsed/Refractory Indolent and Mantle-Cell Non-Hodgkin Lymphoma Friedberg JW et al. Proc ASH 2009;Abstract 924. Introduction > Bendamustine (B)
More informationMathias J Rummel, MD, PhD
I N T E R V I E W Mathias J Rummel, MD, PhD Prof Rummel is Head of the Department of Hematology at the Hospital of the Justus-Liebig University in Gießen, Germany. Tracks 1-17 Track 1 Track 2 Track 3 Track
More informationBendamustine is Effective Therapy in Patients with Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma
Bendamustine is Effective Therapy in Patients with Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma Kahl BS et al. Cancer 2010;116(1):106-14. Introduction > Bendamustine is a novel alkylating
More informationAggressive Lymphomas - Current. Dr Kevin Imrie Physician-in-Chief, Sunnybrook Health Sciences Centre
Aggressive Lymphomas - Current Dr Kevin Imrie Physician-in-Chief, Sunnybrook Health Sciences Centre Conflicts of interest I have no conflicts of interest to declare Outline What does aggressive lymphoma
More informationR/R DLBCL Treatment Landscape
An Updated Analysis of JULIET, a Global Pivotal Phase 2 Trial of Tisagenlecleucel in Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Abstract S799 Borchmann P, Tam CS, Jäger U,
More informationMANTLE CELL LYMPHOMA
MANTLE CELL LYMPHOMA CLINICAL CASE PRESENTATION Martin Dreyling Medizinische Klinik III LMU München Munich, Germany esmo.org Multicenter Evaluation of MCL Annency Criteria fulfilled event free interval
More informationAggressive B-cell Lymphomas
Neoplastic Hematopathology Update 2018 Aggressive B-cell Lymphomas Raju K. Pillai City of Hope National Medical Center I do not have any disclosures Disclosures Outline New entities and changes in WHO
More informationRituximab and Combination Chemotherapy in Treating Patients With Non- Hodgkin's Lymphoma
Page 1 of 5 Home Search Study Topics Glossary Search Full Text View Tabular View No Study Results Posted Related Studies Rituximab and Combination Chemotherapy in Treating Patients With Non- Hodgkin's
More informationLymphomas in Prof Paul Ruff Division of Medical Oncology
Lymphomas in 2010 Prof Paul Ruff Division of Medical Oncology Most Common Lymphomas: ~90% B-cell and ~10% T-cell T lymphoblastic: 2% Marginal zone, nodal: 2% Other: 9% Burkitt: 2% Anaplastic large cell:
More informationStandard Regimens for Haematology
Regimens for Haematology ChlVPP Chlorambucil 6mg/m 2 PO D1 to 14 Vinblastine 6mg/m 2 (max 10mg) IV on D1 & 8 Procarbazine 100mg/m 2 PO on D1 to 14 Prednisolone 40mg PO D1 to 14 ABVD Doxorubicin 25mg/m
More informationORIGINAL ARTICLE. Annals of Oncology 28: , 2017 doi: /annonc/mdx128 Published online 7 April 2017
Annals of Oncology 28: 54 546, 27 doi:.93/annonc/mdx28 Published online 7 April 27 ORIGINAL ARTICLE Outcome of elderly patients with diffuse large B-cell lymphoma treated with R-CHOP: results from the
More informationEmerging targeted therapies for follicular lymphoma A future without chemotherapy
Emerging targeted therapies for follicular lymphoma A future without chemotherapy Pier Luigi Zinzani Institute of Hematology L. e A. Seràgnoli University of Bologna FOLLICULAR LYMPHOMA: GENERAL ASPECTS
More informationNICE guideline Published: 20 July 2016 nice.org.uk/guidance/ng52
Non-Hodgkin s lymphoma: diagnosis and management NICE guideline Published: 20 July 2016 nice.org.uk/guidance/ng52 NICE 2017. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).
More informationLymphoma: What You Need to Know. Richard van der Jagt MD, FRCPC
Lymphoma: What You Need to Know Richard van der Jagt MD, FRCPC Overview Concepts, classification, biology Epidemiology Clinical presentation Diagnosis Staging Three important types of lymphoma Conceptualizing
More informationDefined lymphoma entities in the current WHO classification
Defined lymphoma entities in the current WHO classification Luca Mazzucchelli Istituto cantonale di patologia, Locarno Bellinzona, January 29-31, 2016 Evolution of lymphoma classification Rappaport Lukes
More informationLarge cell immunoblastic Diffuse histiocytic (DHL) Lymphoblastic lymphoma Diffuse lymphoblastic Small non cleaved cell Burkitt s Non- Burkitt s
Non Hodgkin s Lymphoma Introduction 6th most common cause of cancer death in United States. Increasing in incidence and mortality. Since 1970, the incidence of has almost doubled. Overview The types of
More informationAggressive B-cell Lymphomas Updated WHO classification Elias Campo
Aggressive B-cell Lymphomas Updated WHO classification Elias Campo Hospital Clinic, University of Barcelona Diffuse Large B-cell Lymphoma A Heterogeneous Category Subtypes with differing: Histology and
More informationMantle cell lymphoma An update on management
Mantle cell lymphoma An update on management Dr Kim Linton Consultant Medical Oncologist The Christie NHS Foundation Trust 6 th October 2016 This educational meeting is organised and sponsored by Janssen-Cilag
More informationOverview of Lymphoma Clinical Trials
Overview of Lymphoma Clinical Trials Dr Pam McKay Beatson West of Scotland Cancer Centre Lymphoma Action Patient Conference September 2018 Clinical trials medical research involving human participants
More informationWhat is the best approach to the initial therapy of PTCL? standards of treatment? Should all
What is the best approach to the initial therapy of PTCL? standards of treatment? hould all Jia Ruan, M.D., Ph.D. Center for Lymphoma and Myeloma Weill Cornell Medical College New York Presbyterian Hospital
More informationAggressive B cell Lymphomas
Aggressive B cell Lymphomas I have nothing to disclose. Disclosures Raju K. Pillai City of Hope National Medical Center Outline WHO 2016 Classification Large B cell Lymphomas New entities and changes in
More informationPrevalent lymphomas in Africa
Prevalent lymphomas in Africa Dr Zainab Mohamed Clinical Oncologist GSH/UCT Groote Schuur Hospital Disclaimer I declare that I have no conflict of interest Groote Schuur Hospital Denis Burkitt 1911-1993
More informationHIGH GRADE B-CELL LYMPHOMA DAVID NOLTE, MD (PGY-2) HUSSAM AL-KATEB, PHD, FACMG DEBORAH FUCHS, MD
HIGH GRADE B-CELL LYMPHOMA DAVID NOLTE, MD (PGY-2) HUSSAM AL-KATEB, PHD, FACMG DEBORAH FUCHS, MD OUTLINE High grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements Patient presentation 2008/2016
More informationThis is a controlled document and therefore must not be changed or photocopied L.80 - R-CHOP-21 / CHOP-21
R- / INDICATION Lymphoma Histiocytosis Omit rituximab if CD20-negative. TREATMENT INTENT Disease modification or curative depending on clinical circumstances PRE-ASSESSMENT 1. Ensure histology is confirmed
More informationHow to incorporate new therapies into the treatment algorithm of patients with mantle cell lymphoma
How to incorporate new therapies into the treatment algorithm of patients with mantle cell lymphoma Dr. Guillermo Rodríguez García Hospital Universitario Virgen Macarena Hospital Universitario Virgen del
More informationLymphocyte Predominant Hodgkin s Lymphoma. Case Presentation. How would you treat the patient?
Lymphocyte Predominant Hodgkin s Lymphoma Wei Ai, MD, PhD Assistant Clinical Professor University of California, San Francisco January 2010 Case Presentation 32 yo male, diagnosed with stage IIIA lymphocyte
More informationGenomics in diffuse large B cell lymphoma (DLBCL) not as useful as we thought. OR IS IT?
Genomics in diffuse large B cell lymphoma (DLBCL) not as useful as we thought. OR IS IT? Matt McKinney MD Instructor in Medicine, Division of Hematologic Malignancies, Department of Medicine Duke University
More informationOptions in Mantle Cell Lymphoma Therapy
Options in Mantle Cell Lymphoma Therapy Carlo Visco, MD Dept of Cell Therapy and Hematology San Bortolo Hospital, Vicenza, taly My Disclosures: ADVSOR OR ADVSORY BOARDS: Lundbeck Canada nc, Celgene Europe,
More informationOverview. Table of Contents. A Canadian perspective provided by Isabelle Bence-Bruckler, MD, FRCPC
2 A C A N A D I A N P E R S P E C T I V E Volume 2 November 2005 Overview The International Conference on Malignant Lymphoma (ICML) is held every three years in Lugano, Switzerland. ICML started nearly
More informationAggressive B cell Lymphomas
Aggressive B cell Lymphomas Raju K. Pillai City of Hope National Medical Center I have no disclosures Outline What is new in the WHO 2016 classification Insights from genomic studies Double Hit Lymphoma
More informationRecent Advances in the Treatment of Non-Hodgkin s Lymphomas
671 Highlights of the NCCN 18th Annual Conference Recent Advances in the Treatment of Presented by Jeremy S. Abramson, MD, and Andrew D. Zelenetz, MD, PhD Abstract Non-Hodgkin s lymphomas (NHL) represent
More informationAcute Lymphoblastic Leukemia (ALL) Ryan Mattison, MD University of Wisconsin March 2, 2010
Acute Lymphoblastic Leukemia (ALL) Ryan Mattison, MD University of Wisconsin March 2, 2010 ALL Epidemiology 20% of new acute leukemia cases in adults 5200 new cases in 2007 Most are de novo Therapy-related
More informationCLL: disease specific biology and current treatment. Dr. Nathalie Johnson
CLL: disease specific biology and current treatment Dr. Nathalie Johnson Disclosures Consultant and Advisory boards Roche, Abbvie, Gilead, Jansson, Lundbeck,Merck Research funding Roche, Abbvie, Lundbeck
More informationLymphoma- Med A-new drugs and treatments
Lymphoma- Med A-new drugs and treatments Silvia Montoto Lisbon, 19/03/2018 #EBMT18 www.ebmt.or Disclosures: Roche, Gilead Silvia Montoto Lisbon, 19/03/2018 #EBMT18 www.ebmt.or Outline Lymphoma- what is
More informationTRANSPARENCY COMMITTEE OPINION. 27 January 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 27 January 2010 TORISEL 25 mg/ml, concentrate for solution and diluent for solution for infusion Box containing 1
More informationLymphoma 101. Nathalie Johnson, MDPhD. Division of Hematology Jewish General Hospital Associate Professor of Medicine, McGill University
Lymphoma 101 Nathalie Johnson, MDPhD Division of Hematology Jewish General Hospital Associate Professor of Medicine, McGill University Disclosures Consultant and Advisory boards for multiple companies
More informationTransformed lymphoma: biology and treatment
Transformed lymphoma: biology and treatment Silvia Montoto Centre for Haemato-Oncology Barts Cancer Institute 1.00 0.75 0.50 0.25 0.00 N =330 0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 Years %Viability
More informationMANAGEMENT OF LYMPHOMAS
MANAGEMENT OF LYMPHOMAS Challenges & Recommendations F. Chite Asirwa, MD. Internal Medicine Physician Medical Oncologist & Hematologist Director-AMPATH Oncology & Hematology @Kenya Physicians Association
More information